These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10770790)

  • 1. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.
    Speck RR; Flexner C; Tian CJ; Yu XF
    Antimicrob Agents Chemother; 2000 May; 44(5):1397-403. PubMed ID: 10770790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.
    Davis DA; Soule EE; Davidoff KS; Daniels SI; Naiman NE; Yarchoan R
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3620-8. PubMed ID: 22508308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
    Lindhofer H; von der Helm K; Nitschko H
    Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.
    Zennou V; Mammano F; Paulous S; Mathez D; Clavel F
    J Virol; 1998 Apr; 72(4):3300-6. PubMed ID: 9525657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of protease inhibitors on HIV-1 maturation and infectivity.
    Jardine DK; Tyssen DP; Birch CJ
    Antiviral Res; 2000 Jan; 45(1):59-68. PubMed ID: 10774590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1.
    Huang Y; Khorchid A; Wang J; Parniak MA; Darlix JL; Wainberg MA; Kleiman L
    J Virol; 1997 Jun; 71(6):4378-84. PubMed ID: 9151827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
    Liao WH; Wang CT
    Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner.
    Lee YM; Tian CJ; Yu XF
    J Virol; 1998 Nov; 72(11):9061-8. PubMed ID: 9765451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics analysis of consecutive HIV proteolytic cleavages of the Gag-Pol polyprotein.
    Rasnick D
    J Biol Chem; 1997 Mar; 272(10):6348-53. PubMed ID: 9045655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coding sequences upstream of the human immunodeficiency virus type 1 reverse transcriptase domain in Gag-Pol are not essential for incorporation of the Pr160(gag-pol) into virus particles.
    Chiu HC; Yao SY; Wang CT
    J Virol; 2002 Apr; 76(7):3221-31. PubMed ID: 11884546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation.
    Quillent C; Borman AM; Paulous S; Dauguet C; Clavel F
    Virology; 1996 May; 219(1):29-36. PubMed ID: 8623542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1.
    Chen N; Morag A; Almog N; Blumenzweig I; Dreazin O; Kotler M
    J Gen Virol; 2001 Mar; 82(Pt 3):581-590. PubMed ID: 11172099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein.
    Liu H; Wu X; Xiao H; Conway JA; Kappes JC
    J Virol; 1997 Oct; 71(10):7704-10. PubMed ID: 9311854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
    Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
    J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
    Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
    Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells.
    Pettit SC; Sanchez R; Smith T; Wehbie R; Derse D; Swanstrom R
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):1007-14. PubMed ID: 9686647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.